Global Tuberculosis Report 2026 web banner

4.1 Financing for TB prevention, diagnostic and treatment services

Progress in reducing the burden of tuberculosis (TB) disease requires adequate and sustained funding over many years. Since 2002, the World Health Organization (WHO) has monitored funding for TB prevention, diagnostic and treatment services using data reported by national TB programmes (NTPs) through annual rounds of global TB data collection. Findings have been published in global TB reports and peer-reviewed publications (1–3). Recognizing that not all international donor funding for TB is captured in the data reported to WHO, this analysis is complemented each year by analysis of donor funding that is reported to the Organisation for Economic Co-operation and Development (see Section 4.2). Since 2005, funding for TB research has been monitored by Treatment Action Group, with findings published in an annual report (4).

At the second United Nations (UN) high-level meeting on TB in 2023, Member States committed to mobilizing at least US$ 22 billion per year for TB prevention, diagnostic and treatment services by 2027, and US$ 35 billion per year by 2030. A target of US$ 5 billion per year by 2027 was set for investment in TB research (5). These targets were based on estimates of resource needs set out in the latest Global Plan to End TB produced by the Stop TB Partnership (6).

The global landscape of funding for international development, including the health sector, changed substantially in 2025 (7, 8). Overall, official development assistance fell by 23% between 2024 and 2025 (9). The amount of funding raised in 2025 for the eighth replenishment of The Global Fund, to fund grants for HIV, malaria and TB in the period 2026–2028, was 20% lower than the amount raised for the previous cycle (8, 10). In this webpage, country-reported funding data for 2025 are used to assess whether these changes in the donor landscape were reflected in funding reported by NTPs, including through aggregate trends and country-specific analyses.

Reported data

Data on funding available for TB prevention, diagnostic and treatment services, by source of funding and major category of expenditure, were reported to WHO by 131 low and middle-income countries (LMICs) for the period 2015–2025 (Fig. 4.1.1). These countries accounted for 99% of reported TB cases globally in 2025.

Fig. 4.1.1 The 131 low- and middle-income countriesa included in WHO analyses of TB financing, 2015–2025

Fig. 4.1.1 The 131 low- and middle-income countries included in WHO analyses of TB financing, 2015–2025

 

a In the most recent classification of countries by income group published by the World Bank (11), the Russian Federation was categorized as a high-income country. It was included in all analyses because it was an upper-middle-income country for most of the period 2015–2025, is in WHO’s list of high burden countries for drug-resistant TB and was one of the three countries in WHO’s list of global TB watchlist countries until 2025 (having been in WHO’s list of high TB burden countries until 2020). For more details about WHO’s lists of high burden countries for TB, drug-resistant TB and TB/HIV, see Annex 3 of the core report document.


Funding available for TB prevention, diagnostic and treatment services, by source

Funding available for TB prevention, diagnostic and treatment services in LMICs has remained well below the global targets set at the 2023 UN high-level meeting (Fig. 4.1.2). In 2025, total funding was US$ 6.6 billion, an increase of US$ 0.55 billion compared with 2024, mainly attributable to increased domestic funding in India, Indonesia and the Russian Federation.

Throughout the period 2015–2025, the distribution of funding by source remained broadly unchanged, with domestic sources consistently accounting for the majority of funding (Fig. 4.1.2). In 2025, 86% of the total funding for TB prevention, diagnostic and treatment services was from domestic sources. International donor funding for LMICs remained stable between 2015 and 2024, at US$ 1.1–US$ 1.3 billion per year. However, it declined from US$ 1.1 billion in 2024 to US$ 0.94 billion in 2025, a 14% reduction. A similar relative reduction in international donor funding has been reported for HIV, with a decline of 18%, from US$ 8.8 billion in 2024 to US$ 7.3 billion in 2025 (12, 13).

Fig. 4.1.2 Funding available for TB prevention, diagnostic and treatment services in 131 low- and middle-income countries by source,a,b,c,d 2015–2025

a Values for 2015–2024 are higher than those shown in the Global Tuberculosis Report 2025 (14), since they have been inflated (for comparability with data for 2025) to constant US$ values for 2025.
b The 131 countries included in the analysis accounted for 99% of TB cases notified globally in 2025. For 12 countries (0.55% of global TB notifications), funding data for 2025 were not reported to WHO and could not be estimated from available information. For these countries, estimates included only the financial costs associated with inpatient and outpatient treatment.
c In the latest World Bank income classification, the Russian Federation was categorized as a high-income country (11). It was nevertheless included in all analyses because it was classified as an upper-middle-income country for most of the period 2015–2025, remains on WHO’s list of high burden countries for drug-resistant TB, and was included in WHO’s list of global TB watchlist countries until 2025 (having been in WHO’s list of high TB burden countries until 2020). Further details on WHO’s lists of high burden countries for TB, drug-resistant TB and TB/HIV are provided in Annex 3 of the core report.
d Domestic funding in this graphic includes funding reported by NTPs and WHO estimates of the financial costs of inpatient and outpatient care required during TB treatment. Further details are provided in Box 4.1.


Aggregate estimates of the share of funding from domestic and international sources in LMICs are strongly influenced by Brazil, the Russian Federation, India, China and South Africa (BRICS) (Fig. 4.1.3). Together, these countries accounted for US$ 3.7 billion, or 65% of the total of US$ 5.6 billion that was available from domestic sources in 2025. Overall, 97% of available funding in BRICS was from domestic sources; in Brazil, China and the Russian Federation, all funding was from domestic sources.

In other LMICs, international donor funding remains critical. In 2025, it accounted for 43% of the funding available in the 26 high TB burden and 2 global TB watchlist countries (Gabon and Liberia) outside BRICS, and for 56% of the funding available in low-income countries (LICs). These figures are similar to the share of total funding for the HIV response in LMICs that was provided from international donor sources in 2025, which was 41% (12).

reduction in international donor funding for TB between 2024 and 2025 primarily impacted high TB burden countries outside BRICS; and within this category, reductions mostly affected lower-middle-income countries in Asia (the WHO South-East Asia and Western Pacific regions).

 

Fig. 4.1.3 Funding available for TB prevention, diagnostic and treatment services from domestic sourcesa and international donors in 9 country groups, 2015–2025

BRICS: Brazil, the Russian Federation, India, China, South Africa.
a Domestic funding in this graphic includes funding reported by NTPs and WHO estimates of the financial costs of inpatient and outpatient care required during TB treatment. Further details are provided in Box 4.1.
b BRICS refers only to the five original member countries of the BRICS group of countries (Brazil, the Russian Federation, India, China and South Africa). Although the group expanded in 2024, analyses in this report are restricted to the original five members.
c The 2 global TB watchlist countries included are Gabon and Liberia.
d Asia includes the WHO regions of South-East Asia and the Western Pacific.
e “Other regions” consists of three WHO regions: the Eastern Mediterranean Region, the European Region and the Region of the Americas.


The Global Fund is the main source of international donor funding for TB (15). In 2025, it accounted for 79% of the international donor funding reported by NTPs to WHO. Beyond 2025, funding from The Global Fund for TB is likely to decline. As noted above, US$ 12.6 billion was mobilized for HIV, malaria and TB in the Fund’s 2025 replenishment for the 2026-2028 grant cycle, down from US$ 15.7 billion for the 2023–2025 cycle (8, 10).

Section 4.2 provides a more comprehensive analysis of international donor funding for TB during 2013–2024, including funding that is not channelled through NTPs (data for 2025 are not yet available). During this period, the US government (USG) remained both the largest contributor of funding to The Global Fund and the largest bilateral donor for TB, accounting for approximately 50% of international donor funding for TB overall.


Trends in domestic and international donor funding for TB vary among the 30 high TB burden countries and 2  global TB watchlist countries (Fig. 4.1.4).

Fig. 4.1.4 Funding available for TB prevention, diagnostic and treatment services in the 30 high TB burden countries and 2 global TB watchlist countries,a disaggregated by source of funding, 2015–2025

NTP: national TB programme; IP: inpatient; OP: outpatient. The dark blue line includes both funding reported by NTPs and WHO estimates of the financial costs of inpatient and outpatient care.
a The 2 global TB watchlist countries are Gabon and Liberia; for further details, see Annex 3 of the core report document. The Russian Federation is included because it had the largest amount of domestic funding among all countries included in the analysis for the period 2015–2025, is in WHO’s list of high burden countries for drug-resistant TB and was one of the three countries in WHO’s list of global TB watchlist countries until 2025 (having been in WHO’s list of high TB burden countries until 2020).


Given changes in the landscape of international donor funding for health in 2025, trends in funding for TB between 2024 and 2025 warrant specific attention, especially in countries that received both bilateral USG funding and grants from the Global Fund in 2024. Of the 24 countries that were priorities for USG bilateral funding in 2024, 23 have reported data on funding to WHO, both overall and by source, for all years between 2020 and 2025. These data reveal considerable variation in terms of how total funding changed between 2024 and 2025, and its distribution by source (Fig. 4.1.5).

Fig. 4.1.5 Funding available for TB prevention, diagnostic and treatment services in 23 countriesa that were USG priorities for bilateral funding for TB and that received grants from the Global Fund in 2024, by source of funding,b 2020–2025

a The figure includes 23 of the 24 countries that were USG priorities for bilateral funding for TB in 2024. Data were not available for Uzbekistan.
b Domestic funding in this graphic is based on data reported by NTPs, which typically do not include the financial costs associated with inpatient and outpatient care required during TB treatment.


Five patterns and associated country categories can be distinguished:

  • An increase in both total funding and funding from USG bilateral sources between 2024 and 2025. This category comprises six countries: Kyrgyzstan, Mozambique, Uganda, the United Republic of Tanzania, Viet Nam and Zambia.
  • An increase in total funding between 2024 and 2025, despite a reduction in USG bilateral funding, owing to an increase in domestic funding or support from the Global Fund. This category comprises six countries: Afghanistan, the Democratic Republic of the Congo, India, Indonesia, the Philippines and South Africa.
  • An increase in total funding in 2025, with no USG funding reported in either 2024 or 2025. This category comprises one country, Pakistan, where funding from Global Fund grants increased between 2024 and 2025.
  • A slight decline in total funding between 2024 and 2025, despite a small increase in USG bilateral funding. This category comprises one country, Kenya.
  • A reduction in both total funding and USG bilateral funding between 2024 and 2025. This category comprises 9 countries: Bangladesh, Cambodia, Ethiopia, Malawi, Myanmar, Nigeria, Tajikistan, Ukraine and Zimbabwe.

 

These patterns highlight the importance of assessing 2024–2025 financing trends at country level, from both domestic and international donor sources. They also appear to reflect new modalities for USG bilateral funding; for example, the replacement of funding previously provided by the United States Agency for International Development (USAID) with new forms of bilateral support (16, 17).


Among the 15 countries that reported receiving USG bilateral funding in 2025, this funding accounted for 20% or more of total available funding in 7 countries; the share exceeded 30% in Mozambique, Uganda, the United Republic of Tanzania and Zambia (Fig. 4.1.6). Fourteen of the 15 countries were highly reliant on Global Fund grants in 2025; the exception was India.

Fig. 4.1.6 Sources of funding availablea for TB prevention, diagnostic and treatment services in 2025, for 15 countriesb that reported receiving USG bilateral funding and Global Fund grants in 2025

a Domestic funding in this graphic is based on data reported by NTPs, which typically do not include the financial costs associated with inpatient and outpatient care required during TB treatment.
b In addition, 9 countries were USG priorities for bilateral funding for TB in 2024 but are not shown in the figure. Eight reported no USG bilateral funding in 2025: Afghanistan, Bangladesh, the Democratic Republic of the Congo, Malawi, Pakistan, Tajikistan, South Africa and Zimbabwe. Data were not reported by Uzbekistan.


Funding for TB prevention, diagnostic and treatment services, by category of expenditure

Funding available for the diagnosis and treatment of drug-susceptible TB declined between 2017 and 2022, but increased during 2023–2025 (Fig. 4.1.7 below). This trend was strongly influenced by patterns in BRICS (Fig. 4.1.8), which account for a large share of domestic funding for TB prevention, diagnostic and treatment services (Fig. 4.1.3). Funding available for TB preventive treatment has been reported separately since 2019 and remained a small share of total funding throughout the period.

Funding available for treatment and management of drug-resistant TB increased between 2015 and 2022, but then declined during 2023–2025, returning to around its 2015 level. Explanations include the scale-up of shorter all-oral regimens, including 6-month regimens, which have reduced health service utilization in many settings (see also Fig. 2.4.10 of Section 2.4); and reductions in the cost of these regimens.

Fig. 4.1.7 Funding available for TB prevention, diagnostic and treatment services in total and by category of expenditure in 131 low- and middle-income countries,a 2015–2025

a The 131 countries included in the analysis accounted for 99% of TB cases notified globally in 2025. Although categorized as a high-income country in the latest World Bank income classification (11), the Russian Federation was included for consistency with other analyses in this section. Further details are provided in Annex 3 of the core report document.
b Drug-susceptible TB includes funding reported by NTPs for laboratory equipment and supplies, anti-TB drugs, programme management (including staff and activities), operational research and surveys, patient support and miscellaneous items. It also includes WHO estimates of funding for inpatient and outpatient care for people treated for drug-susceptible TB, based on WHO estimates of the unit costs of bed-days and visits and the average number of outpatient visits and bed-days per TB patient reported by NTPs.
c Drug-resistant TB includes funding reported by NTPs for anti-TB drugs required for treatment of multidrug and rifampicin-resistant TB, including pre-extensively drug-resistant TB and extensively drug-resistant TB; programme management (staff and activity) costs specifically required for the provision of care to people with drug-resistant TB; and WHO estimates of funding for inpatient and outpatient care. Funding reported to WHO does not allow the costs of diagnosis of drug-resistant TB to be separately distinguished; laboratory supplies and equipment is allocated to drug-susceptible TB. Rapid tests recommended by WHO can detect TB and RR-TB simultaneously.
d Data for TB preventive treatment (drugs only) are only available from 2019 onwards.


Fig. 4.1.8 Funding available for drug-susceptible TB and drug-resistant TB in three country groups, 2015–2025

BRICS: Brazil, the Russian Federation, India, China, South Africa.
a BRICS refers to the five original members countries; analysis in this report is restricted to these countries.
b The 2 global TB watchlist countries included are Gabon and Liberia.
c,d The categories of drug-susceptible TB and drug-resistant TB categories are defined in Fig. 4.1.7


Funding gaps for implementation of national strategic plans for TB

Data about required budgets and expected funding for the implementation of national strategic plans for TB, and associated sources of funding, are reported to WHO by NTPs as part of WHO’s annual rounds of global TB data collection. Funding gaps, as identified by NTPs, were estimated based on the difference between (i) the required budget and (ii) the expected level of funding.

In 2026, 54 of the 131 LMICs reported that funding was not sufficient for full implementation of their national strategic plans for TB (Fig. 4.1.9).

Fig. 4.1.9 The 131 low- and middle-income countriesa that did and did not report funding gaps for full implementation of their national strategic plans for TB in 2026

 

Fig. 4.1.9 The 131 low- and middle-income countries that did and did not report funding gaps for full implementation of their national strategic plans for TB in 2026
a The 131 countries accounted for 99% of the global number of notified cases of TB in 2025. In the most recent classification of countries by income group published by the World Bank (11), the Russian Federation was categorized as a high-income country. It was included in all analyses because it was an upper-middle-income country for most of the period 2015–2025, is in WHO’s list of high burden countries for drug-resistant TB and was one of the three countries in WHO’s list of global TB watchlist countries until 2025 (having been in WHO’s list of high TB burden countries until 2020). For more details about WHO’s lists of high burden countries for TB, drug-resistant TB and TB/HIV, see Annex 3 of the core report document.


The combined total of the funding gaps reported by these 54 countries for 2026 was US$ 1.7 billion. The largest gaps were reported by countries in the WHO African and Western Pacific regions. In terms of country income groups, the largest gap was reported by upper-middle-income countries, at US$ 0.95 billion in 2026, up from US$ 0.46 billion in 2025; this increase was mainly attributable to funding gaps reported by Indonesia and the Philippines (Fig. 4.1.10 below, and Fig. 4.1.11). Among the 25 LICs, 13 (52%) reported funding gaps that amounted to US$ 205 million in 2026 (Fig. 4.1.10).

Fig. 4.1.10 Gaps between the funding required for national strategic plans for TB and the expected level of funding as reported by national TB programmes,a by income group and by WHO region, 2015–2026

a A total of 54 low- and middle-income countries reported insufficient funding for full implementation of their national strategic plans for TB in 2026.


Among the 30 high TB burden countries and 2 global TB watchlist countries, the largest gaps for 2026 were reported by Indonesia (US$ 535 million), the Philippines (US$ 199 million), Bangladesh (US$ 183 million), Kenya (US$ 121 million) and Nigeria (US$ 85 million) (Fig. 4.1.11).

Fig. 4.1.11 Sources of expected fundinga and funding gaps reported for the TB-specific budgets included in national strategic plans for TB in the 30 high TB burden countries and 2 global TB watchlist countries,b 2026c



a Domestic funding in this graphic is based on data reported by NTPs, which typically do not include the financial costs associated with inpatient and outpatient care required during TB treatment.
b The 2 global TB watchlist countries are Gabon and Liberia; for further details, see Annex 3 of the core report document.
c Two countries - the Democratic People’s Republic of Korea and Liberia - had not reported budget data for 2026 to WHO at the time the data snapshot for this webpage was taken (25 August 2026).
d In the most recent classification of countries by income group published by the World Bank (11), the Russian Federation was categorized as a high-income country. It was included as an upper-middle-income country because it was an upper-middle-income country for most of the period 2015–2025, is in WHO’s list of high burden countries for drug-resistant TB and was one of the three countries in WHO’s list of global TB watchlist countries until 2025 (having been in WHO’s list of high TB burden countries until 2020). For more details about WHO’s lists of high burden countries for TB, drug-resistant TB and TB/HIV, see Annex 3 of the core report document.


The Stop TB Partnership’s Global Plan to End TB (the Global Plan) for 2023–2030 estimated global funding needs of US$ 15–32 billion per year in LMICs. For 2026, estimated needs were US$ 21 billion, comprising US$ 2.5 billion for LICs, US$ 12 billion for lower-middle-income countries and US$ 6.4 billion for upper-middle-income countries (6).

Overall, the total required budget reported by LMICs to WHO for 2026 was only 39% of the estimated needs for LMICs in 2026 in the Global Plan (Fig. 4.1.12). This large difference probably reflects the lower ambition, scale and scope of national strategic plans compared with the Global Plan. National plans are also likely to be influenced by expected resource constraints, including the domestic and international funding that countries anticipate will be available.

For example, the funding gap reported by LICs for 2026 was US$ 0.21 billion. This was equivalent to only 9.4% of the gap between estimated needs in the Global Plan for LICs and their expected funding. The Global Plan estimated needs of US$ 2.5 billion for LICs in 2026, compared with expected funding of US$ 0.32 billion, implying a gap of US$ 2.2 billion (6).

This comparison suggests that NTP-reported funding gaps may reflect resource-constrained national planning, rather than the full additional investment needed to reach the levels set out in the Global Plan.

Fig. 4.1.12 Gaps between the funding required for national strategic plans for TB as reported by NTPsa and the estimated funding needs in the Global Plan, by income group, 2026

a The Global Plan estimates include the financial costs associated with inpatient and outpatient care required during TB treatment, which are not typically included in data reported by NTPs. For comparability purposes, the estimated financial costs associated with inpatient and outpatient treatment were added to the required budgets and expected funding reported by NTPs, using the latest available information (2025). See Box 4.1 for the methods used to develop these estimates.


Increases in both domestic and international funding for TB are urgently required. Variation in the share of funding from domestic sources among countries within the same income group suggests that there is scope to increase domestic funding in some high TB burden and global TB watchlist countries, while international donor funding remains critical for LICs and many high TB burden countries outside BRICS. Mobilizing additional resources is particularly urgent given substantial changes to the international donor funding landscape in 2025 and a more constrained funding environment for 2026–2028 (8–10, 12–17).


Estimated cost per person treated for TB

The median provider cost per person treated for drug-susceptible TB in 2025 was US$ 808 (Fig. 4.1.13).

Fig. 4.1.13 Estimated cost per person treated for drug-susceptible TBa compared with GDP per capita in 117 countries,b 2025

Red dots indicate the 30 high TB burden and 2 global TB watchlist countries, blue dots indicate other countries; the size of each dot is proportional to the number of national notifications of people diagnosed with drug-susceptible TB in 2025. Put cursor over a dot to see the country name and data.

a The following costs are included: laboratory equipment and supplies; anti-TB drugs; programme management (including staff and activities); operational research and surveys; patient support; miscellaneous items; inpatient and outpatient care.
b Limited to countries with at least 100 people on first-line treatment in 2025 and that reported funding and utilisation data to WHO.


The median provider cost per person treated for drug-resistant TB in 2025 was US$ 4071 (Fig. 4.1.14). This includes treatment costs and TB programme-related costs. Between 2023 and 2025, the median cost decreased by around US$ 1000 per person, probably reflecting expanded use of 6-month treatment regimens, first recommended by WHO in 2022 (Fig. 2.4.10 of Section 2.4). Decreases of around US$ 500–1000 were observed in several countries: examples include Indonesia, Myanmar, Peru and Ukraine.

Fig. 4.1.14 Estimated cost per person treated for drug-resistant TBa compared with GDP per capita in 85 countries,b 2025

Red dots indicate the 30 high RR-TB burden countries, blue dots indicate other countries; the size of each dot is proportional to the number of national notifications of people diagnosed with drug-resistant TB in 2025. Put cursor over a dot to see the country name and data.

RR-TB: rifampicin resistant-TB.
a The following costs are included: anti-TB drugs; programme management (staff and activity) costs specifically required for the provision of care to people with drug-resistant TB; inpatient and outpatient care.
b Limited to countries with at least 20 people on second-line treatment in 2025 and that reported funding and utilisation data to WHO.


Estimates of the costs incurred by people with TB and their households during diagnosis and treatment are available from national surveys (Section 5.2).

Further details on funding for TB prevention, diagnostic and treatment services are available in the country profiles of the Global tuberculosis report app. Methods for data collection and analysis are summarized below (Box 4.1).

Data shown on this webpage are as of 25 August 2026 (see Annex 2 of the core report document for more details).


Box 4.1

Methods used to compile, review, validate and analyse financial data reported to WHO

WHO has monitored government and international donor financing for TB prevention, diagnostic and treatment services since 2002. Data are stored in the WHO global TB database. The standard methods used to compile, review, validate and analyse these data are described in detail in a technical appendix; this box provides a summary.

The methods used to systematically review and validate data have remained consistent since 2002. They include routine checks for plausibility and consistency, and discussions with country respondents to resolve queries. In reviewing and validating data, particular attention is given to high TB burden countries or global TB watchlist countries.

Missing data are handled as follows:

  • The analysis of available funding for TB uses reported information on received funding. When received funding is not available for a given year, expenditure data are used; if both received funding and expenditure are unavailable, data on committed funds are used. If none of these data are available, received funding, expenditure or committed funds from adjacent years are used. For analysis of funding in 2025, received funding was replaced by one of these methods for 34 countries, which collectively accounted for 4.2% of the global number of notified cases of TB in 2025. This included 3 high burden and 2 global watchlist countries, Angola, the Democratic People’s Republic of Korea, Gabon, Liberia and South Sudan; these countries accounted for 2.3% of the global number of TB case notifications. Twelve countries, collectively accounting for 0.55% of the global number of notified cases of TB in 2025, did not have sufficient data for any of the above methods to be applied; for these countries, only the estimated financial costs associated with inpatient and outpatient treatment were included, using the methods described below.

  • When the breakdown of received funding by source or by category is missing for a given year, country-specific shares from the previous year are applied instead.

  • Since TB funding reported by NTPs usually excludes the financial costs associated with the inpatient and outpatient care required during TB treatment, country-specific estimates of these costs are added. Exceptions among high TB or RR-TB burden countries include Belarus, China, Kazakhstan and the Russian Federation. Estimates are calculated by multiplying the reported number of TB patients notified by the average number of bed days and outpatient visits per patient, as reported by NTPs, and their respective unit costs. This is done separately for TB patients with drug-susceptible TB and drug-resistant TB. Unit costs are estimated using the WHO CHOosing Interventions that are Cost-Effective (WHO-CHOICE) methods (18).

Trend data are shown in constant (as opposed to current) 2025 US dollars. In other words, funding amounts are shown in real terms, after adjustment for inflation. Figures and tables that show data for 2025 only are labelled as current 2025 US dollars.

Note: Data sources for Fig 4.1.2–4.1.14: Data reported by NTPs and estimates produced by the WHO Department of HIV, TB, Hepatitis & STIs. The data sources, boundaries, accounting rules, and estimation methods used in this report are different from those of the System of Health Accounts 2011 (SHA 2011) (19).The TB funding data reported here are thus not comparable with the disease expenditure data, including for TB, that are reported in WHO’s Global Health Expenditure Database.

References

  1. Floyd K, Fitzpatrick C, Pantoja A, Raviglione M. Domestic and donor financing for tuberculosis care and control in low-income and middle-income countries: an analysis of trends, 2002–11, and requirements to meet 2015 targets. Lancet Glob Health. 2013;1(2):e105–15 (https://doi.org/10.1016/s2214-109x(13)70032-9).

  2. Floyd K, Pantoja A, Dye C. Financing tuberculosis control: the role of a global financial monitoring system. Bull World Health Organ. 2007;85(5):334–40 (https://doi.org/10.2471/blt.06.034942).

  3. Su Y, Garcia Baena I, Harle AC, Crosby SW, Micah AE, Siroka A et al. Tracking total spending on tuberculosis by source and function in 135 low-income and middle-income countries, 2000-17: a financial modelling study. Lancet Infect Dis. 2020;20:929-42 (https://doi.org/10.1016/S1473-3099(20)30124-9).

  4. Treatment Action Group, Stop TB Partnership. Tuberculosis research funding trends 2005–2023. New York: Treatment Action Group; 2024 (https://www.treatmentactiongroup.org/wp-content/uploads/2024/12/TB_funding_2024_final.pdf).

  5. Resolution 78/5: Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis. New York: United Nations; 2023 (https://undocs.org/A/RES/78/5).

  6. The Global Plan to End TB, 2023–2030. Geneva: Stop TB Partnership; 2022 (https://www.stoptb.org/global-plan-to-end-tb/global-plan-to-end-tb-2023-2030).

  7. A historic decline in foreign aid: Preliminary 2025 ODA data [website]. Paris: Organisation for Economic Co-operation and Development; 2026 (https://www.oecd.org/en/data/insights/data-explainers/2026/04/a-historic-decline-in-foreign-aid-preliminary-2025-oda-data.html).

  8. Global Fund Board welcomes final eighth replenishment outcome of US$12.64 billion, backs strategic shifts to advance countries’ path to self-reliance [website]. Global Fund to Fight AIDS, Tuberculosis and Malaria; 2026 (https://www.theglobalfund.org/en/news/2026/2026-02-18-global-fund-board-welcomes-final-eighthreplenishment-outcome/).

  9. OECD data shows brutal drop in development assistance [website]. African Business; 2026 (https://african.business/2026/04/politics/oecd-data-shows-brutal-drop-in-development-assistance).

  10. Global Fund board hails record-breaking seventh replenishment final outcome of US$15.7 billion [website]. Global Fund to Fight AIDS, Tuberculosis and Malaria; 2022 (https://www.theglobalfund.org/en/news/2022/2022-11-18-global-fund-board-hails-record-breaking-seventhreplenishment-final-outcome-of-usd157-billion/).

  11. World Bank Country and Lending Groups. Washington D.C.: World Bank; 2026 (https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups).

  12. UNAIDS Special report for the 26th International AIDS Conference: united to end AIDS. Geneva: Joint United Nations Programme on HIV/AIDS; 2026 (https://www.unaids.org/en/resources/documents/2026/20260727_special_report_AIDS2026).

  13. UNAIDS HIV Financial Dashboard [website]. Geneva: Joint United Nations Programme on HIV/AIDS; 2026 (https://hivfinancial.unaids.org/hivfinancialdashboards.html).

  14. Global Tuberculosis Report 2025. Geneva: World Health Organization; 2025 (https://iris.who.int/handle/10665/383364). License: CC BY-NC-SA 3.0 IGO.

  15. The Global Fund; Geneva: (https://www.theglobalfund.org/en/).

  16. State Department outlines plans to move from global health aid to self-reliance [website]. The Hill; 2025 (https://thehill.com/homenews/administration/5511388-us-health-aid-reform/).

  17. America First global health strategy [website]. US Department of State; 2025 (https://www.state.gov/america-first-global-health-strategy).

  18. Stenberg K, Lauer JA, Gkountouras G, Fitzpatrick C, Stanciole A. Econometric estimation of WHO-CHOICE country-specific costs for inpatient and outpatient health service delivery. Cost Eff Resour Alloc. 2018;16:11 (https://doi.org/10.1186/s12962-018-0095-x).

  19. Organisation for Economic Co-operation and Development, Eurostat and World Health Organization (2017). A System of Health Accounts 2011: Revised edition. Paris: OECD Publishing; 2017 (http://dx.doi.org/10.1787/9789264270985-en).

General disclaimers
The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.